DNA Damage Repair Inhibitors—Combination Therapies

Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors

(2021) Khanh T. Do et al.   CLINICAL CANCER RESEARCH

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

(2021) Diana Zatreanu et al.   Nature Communications

ATM: Main Features, Signaling Pathways, and Its Diverse Roles in DNA Damage Response, Tumor Suppression, and Cancer Development

(2021) Liem Minh Phan et al.   Genes

The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer

(2020) G. Mauri et al.   ANNALS OF ONCOLOGY

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

(2020) Hyoung Kim et al.   Nature Communications

Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis

(2019) Amirali B. Bukhari et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.

(2019) Arjun Mittra et al.   JOURNAL OF CLINICAL ONCOLOGY

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy

(2019) Charlie Gourley et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic determinants of cellular addiction to DNA polymerase theta

(2019) Wanjuan Feng et al.   Nature Communications

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

(2018) Alan Ashworth et al.   Nature Reviews Clinical Oncology

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

(2018) Juan Jin et al.   NEOPLASIA

Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer

(2018) Panagiotis A. Konstantinopoulos et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

State-of-the-art strategies for targeting the DNA damage response in cancer

(2018) Patrick G. Pilié et al.   Nature Reviews Clinical Oncology

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells

(2017) Stephanie A. Yazinski et al.   GENES & DEVELOPMENT

Non-homologous DNA end joining and alternative pathways to double-strand break repair

(2017) Howard H. Y. Chang et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeting the ATR-CHK1 Axis in Cancer Therapy

(2017) Stuart Rundle et al.   Cancers

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models

(2016) Hyoung Kim et al.   CLINICAL CANCER RESEARCH

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors

(2016) Jessica S. Brown et al.   Cancer Discovery

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

(2016) Junko Murai et al.   Oncotarget

Targeting the DNA Damage Response in Cancer

(2015) Mark J. O’Connor   MOLECULAR CELL

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition

(2015) Fiona K. Middleton et al.   Oncotarget

ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency

(2014) K. N. Mohni et al.   CANCER RESEARCH

Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines

(2014) Eiji Kubota et al.   CELL CYCLE

ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status

(2013) C. J. Huntoon et al.   CANCER RESEARCH

ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition

(2013) Maria Gilardini Montani et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The roles of ARID1A in gynecologic cancer

(2013) Tsui-Lien Mao et al.   Journal of Gynecologic Oncology

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

(2011) A Peasland et al.   BRITISH JOURNAL OF CANCER

DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells

(2011) Zhiyong Mao et al.   CELL CYCLE

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

(2011) Philip M Reaper et al.   Nature Chemical Biology

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE

ATR: an essential regulator of genome integrity

(2008) Karlene A. Cimprich et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY